In 2018 the first clinical trial of gene therapy for LGMD2E started in the United States.
Gene Delivery Clinical Trial of SRP-9003 for Patients With LGMD2E (Beta-sarcoglycan Deficiency)
On 2013 a gene therapy clinical trial for LGMD2D started in the United States carried out by dr. Jerry Mendell.
In 2011, a gene therapy clinical trial was carried out in France for LGMD2C by dr. Serge Herson.
On 2007, a gene therapy clinical trial was carried out in the United States by Dr. Jerry Mendell
15 October 2020 | Clinical trials
SRP-9003 Gene Therapy for LGMD2E Shows Benefit after 1 year - Muscular Dystrophy News Today - June 9 2020
New data gives hope for Limb Girdle Muscular Dystrophy gene therapy - Patient Worthy - June 17, 2020
31 December 2019 | Clinical trials
SRP-9003 gene therapy shows "very encouraging" results at 9 months in girdle dystrophy - Sarepta Reports - october 9 2019
Myonexus Therapeutics announced the initiation of a trial for the first-ever Gene Therapy for Beta-Sarcoglycanopathy